Delivery Order SPE2DB20D3101-SPE2DB23FRMR0

Award Date 5/26/23
Potential Completion Date 5/30/23
Potential Value $324K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $48,748.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,563,250,472 units of the drug Ondansetron ODT 4 mg tablet, with a performance period through January 8, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4566054300 units of Ondansetron ODT 4 mg tablets. The $2,930.68 firm fixed-price contract has an ultimate completion date of October 9, 2024 and does not utilize any set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,327.73 Firm Fixed Price Delivery Order is for the supply of 4,564,802,515 units of Ondansetron ODT 4 mg Tablets. The contract has an ultimate completion date of June 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,863.89 firm fixed-price delivery order is for the supply of 4,564,603,718 units of Ondansetron ODT 4 mg tablets in 30-count packages. The contract has a completion date of May 15, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the supply of 4,566,718,302 units of the drug Ondansetron ODT 4 mg tablets in 30-count packages. The $10,031.45 firm fixed-price delivery order contract has an ultimate completion date of December 16, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,517.18 firm fixed-price delivery order is for the supply of 4,566,249,434 units of ondansetron ODT 8 mg tablets. The contract has an ultimate completion date of October 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,971.52 firm-fixed-price delivery order is for the supply of 4,566,948,280 units of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of January 16, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,558.83 fixed-price delivery order is for the supply of 4,563,032,235 units of Ondansetron ODT 4 mg tablets, with a completion date of December 8, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,400.57 firm fixed-price delivery order is for the supply of 4,559,623,831 units of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of January 18, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,555,923 units of Ondansetron ODT 8 mg tablets. The $3,156.38 firm-fixed-price delivery order has a completion date of November 27, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB23FRMR0
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,561,061,764 units of Ondansetron ODT 4 mg Tablets. The $323,712.19 firm fixed-price delivery order contract has a completion date of May 30, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated with a set-aside requirement, indicating open competition. The contract supports the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

Generated 2/27/25, 9:43 AM